Bristol-Myers Squibb Stock News

Investing in high-yielding dividend stocks can result in significant dividend income for your portfolio. But higher yields also tend to mean higher risk, and dividends are never guaranteed.

Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a lineup of blockbuster drugs and a solid pipeline of drugs, an A S&P credit rating, and offers a safe and sizable yield. Rexford Industrial Realty owns high-value, mission-critical real estate, pays a...

Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focused on growth initiatives, including AI-driven drug discovery and new partnerships. Despite near-term earnings declines, due to patent expirations, AI and pipeline opportunities offer potential upside ...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL).

Bristol-Myers Squibb faces political pressure on U.S. drug prices, but I see the risk as manageable given its strong fundamentals. The company's growth portfolio now exceeds half of revenue, offsetting legacy drug declines, and trades at a compelling single-digit P/E ratio. Robust cash flow supports a nearly 6% dividend yield and ongoing share repurchases, while debt remains manageable and on t...

Bristol-Myers Squibb's sales are stabilizing, with Q2 net sales up 1% YoY and growth portfolio drugs like Camzyos and Breyanzi showing strong momentum. Despite margin compression and profitability concerns, operating cash flow surged 70% YoY, supporting continued capital returns to shareholders. The company raised its full-year top-line guidance, signaling less severe declines than feared, thou...

Bristol Myers (BMY) Q2 EPS Jumps 36%

BMY's double-beat FQ2'25 performance and raised FY2025 guidance have been met with much skepticism, as observed in the steep pullback post earnings. This is despite the Growth Portfolio comprising over 50% of its overall revenues, with further expansion likely thanks to its intensified R&D, partnerships, and M&A efforts. BMY's discounted valuations present a deep-value buying opportunity, with ...